• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Bausch Health Companies Inc (NY: BHC )

    8.020 +0.840 (+11.70%)
    Official Closing Price Updated: 4:10 PM EDT, Sep 18, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 8,158,561
    Open 7.480
    Bid (Size) 7.990 (5)
    Ask (Size) 8.020 (5)
    Prev. Close 7.180
    Today's Range 7.390 - 8.110
    52wk Range 3.960 - 11.46
    Shares Outstanding 358,808,755
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Contact Lens Supplier Bausch + Lomb Eyes Sale Amid Separation Challenges As Parent Bausch Health Faces Debt Issues
    Bausch + Lomb is exploring a sale as its parent company, Bausch Health, faces significant debt and creditors' opposition to a spin-off. 
    Via Benzinga
    Topics Supply Chain
    Exposures Supply Chain
    Bausch Reportedly Explores A Sale; Could Alcon, J&J Or AbbVie Buy It?
    Bausch + Lomb is reportedly considering a sale. But its potential acquirers could come up against antitrust concerns. 
    Via Investor's Business Daily

    Performance

    YTD
    +3.08%
    +3.08%
    1 Month
    +39.48%
    +39.48%
    3 Month
    +23.96%
    +23.96%
    6 Month
    -15.93%
    -15.93%
    1 Year
    -4.18%
    -4.18%

    More News

    Read More
    Bank Of Canada Cuts Rates Again As Inflation, Labor Market Cool: Canadian Stocks Rebound, Loonie Strengthens
    Via Benzinga
    Topics Economy
    Exposures Interest Rates
    Bausch Health Announces 2024 Gastrointestinal Health Scholars Program Winners
    Via ACCESSWIRE
    Bausch Health Solvency Remains A Concerns, Analyst Downgrades Stock
    Via Benzinga
    Bausch Health Announces Second Quarter 2024 Results
    Via ACCESSWIRE
    Apple, Amazon, Microsoft, Meta Lead The Charge As Investors Bank On Tech Cheer For Rally's Reacceleration: Week Ahead In Earnings
    Via Benzinga
    Topics Economy
    Exposures Interest Rates
    Bausch Health Responds to Market Rumors
    Via ACCESSWIRE
    US Stocks Tumble On Economic, Geopolitical Concerns; Small Caps, Chipmakers Sink; Meta Rallies: What's Driving Markets Thursday?
    Via Benzinga
    BHC Stock Plunges as Bausch Health Appears on the Brink of Bankruptcy
    Via InvestorPlace
    Topics Bankruptcy
    Exposures Financial Legal
    Bausch Health Welcomes Two New Members to the Executive Leadership Team
    Via ACCESSWIRE
    Bausch Health Announces 2024 Annual Meeting of Shareholder Results
    Via ACCESSWIRE
    Wall Street Looks To Ride On Earnings Cheer As Meta Q2 Impresses Investors: Analyst Says Economic Data, Stock Performances Suggest Republican Win In November
    Via Benzinga
    Why Bausch health Shares Are Falling Today
    Via Benzinga
    Topics Bankruptcy
    Exposures Financial Legal
    Stocks Plummet After Tech Earnings, Manufacturing Data
    Via Talk Markets
    Topics Stocks
    Exposures US Equities
    Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Via Benzinga
    Bausch Health to Announce Second Quarter 2024 Results on August 1, 2024
    Via ACCESSWIRE
    Bausch Health Brings Patent Infringement Lawsuit Against Norwich Pharmaceuticals
    Via ACCESSWIRE
    Bausch Health Reports Promising R&D Trial Updates on Amiselimod and Scientific Data Presented at International Healthcare Conferences
    Via ACCESSWIRE
    Bausch Health, Canada Inc. Announces Additional Public Drug Plan Listings for PrUCERIS(R) (Budesonide) Aerosol Foam To Treat Mild to Moderate Distal Ulcerative Colitis in Adults
    Via ACCESSWIRE
    Salix to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024
    Via ACCESSWIRE
    Bausch Health Announces Updates Related to Norwich XIFAXAN Matters
    Via ACCESSWIRE
    Salix Pharmaceuticals announces Bellamy Young as Spokesperson for Xifaxan(R) (rifaximin)
    Via ACCESSWIRE
    Why Bausch Health Companies Stock Dived by More Than 7% Today
    Via The Motley Fool
    BHC Stock Earnings: Bausch Health Companies Misses EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.